39938-97-1

Basic information

• Product Name: Pentanal, 5-(2,5-dimethylphenoxy)-2,2-dimethyl-
• CAS NO: 39938-97-1
• Molecular Formula: C15H22O2
• Molecular Weight: 234.338
• Mol File: 39938-97-1.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: Pentanal, 5-(2,5-dimethylphenoxy)-2,2-dimethyl-(CAS DataBase Reference)
• NIST Chemistry Reference: Pentanal, 5-(2,5-dimethylphenoxy)-2,2-dimethyl-(39938-97-1)
• EPA Substance Registry System: Pentanal, 5-(2,5-dimethylphenoxy)-2,2-dimethyl-(39938-97-1)

Safety Data

• Hazardous Substances Data: 39938-97-1(Hazardous Substances Data)

Upstream product

• 25812-30-0 gemfibrozil 

Downstream Products

• 1376614-98-0 5-(2,5-dimethylphenoxy)-2,2-dimethylpentanal oxime 
• 1376614-97-9 2-((5,5-dimethoxy-4,4-dimethylpentyl)oxy)-1,4-dimethylbenzene 
• 25812-30-0 gemfibrozil 

Relevant articles and documents

Mechanistic Insights on Reduction of Carboxamides by Diisobutylaluminum Hydride and Sodium Hydride?Iodide Composite

The reaction mechanisms on reduction of tertiary carboxamides by diisobutylaluminum hydride (DIBAL) and sodium hydride (NaH)-sodium iodide (NaI) composite were elucidated by the computational and experimental approaches. Reduction of N,N-dimethyl carboxamides with DIBAL provides the corresponding amines, whereas that with the NaH?NaI composite exclusively forms aldehyde even at high reaction temperature. DFT calculations revealed that dimeric structural nature of DIBAL and Lewis acidity on its Al center play crucial role to decompose the tetrahedral anionic carbinol amine intermediate through C?O bond cleavage. On the other hand, in the reduction with the NaH?NaI composite, the resulting tetrahedral anionic carbinol amine intermediate could be kept stable, thus providing aldehydes as a sole product by the aqueous workup.

Reduction of N,N-Dimethylcarboxamides to Aldehydes by Sodium Hydride–Iodide Composite

A new and concise protocol for selective reduction of N,N-dimethylamides into aldehydes was established using sodium hydride (NaH) in the presence of sodium iodide (NaI) under mild reaction conditions. The present protocol with the NaH-NaI composite allows for reduction of not only aromatic and heteroaromatic but also aliphatic N,N-dimethylamides with wide substituent compatibility. Retention of α-chirality in the reduction of α-enantioriched amides was accomplished. Use of sodium deuteride (NaD) offers a new step-economical alternative to prepare deuterated aldehydes with high deuterium incorporation rate. The NaH-NaI composite exhibits unique chemoselectivity for reduction of N,N-dimethylamides over ketones.

DRUG DERIVATIVES

The present invention relates to derivatives of known active pharmaceutical compounds. These derivatives are differentiated from the parent active compound by virtue of being redox derivatives of the active compound. This means that one or more of the functional groups in the active compound has been converted to another group in one or more reactions which may be considered to represent a change of oxidation state. We refer to these compounds generally as redox derivatives. The derivatives of the invention may be related to the original parent active pharmaceutical compound by only a single step transformation, or may be related via several synthetic steps including one or more changes of oxidation state. In certain cases, the functional group obtained after two or more transformations may be in the same oxidation state as the parent active compound (and we include these compounds in our definition of redox derivatives). In other cases, the oxidation state of the derivative of the invention may be regarded as being different from that of the parent compound. In many cases, the compounds of the invention have inherent therapeutic activity on their own account. In some cases, this activity relative to the same target or targets of the parent compound is as good as or better than the activity which the parent compound has against the target or targets.